Two-year results of the ATTRACT trial show that pharmacomechanical catheter-directed thrombolysis (PCDT) to treat deep-vein thrombosis does not reduce the patients’ chances of developing post-thrombotic syndrome, but does increase their risk of major bleeding compared anticoagulation drug therapy alone.
“[ATTRACT] provides the first high quality data on PCDT and will enable doctors to target its use to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?